SRM-IV眩晕诊疗系统联合倍他司汀治疗半规管耳石症致前庭周围性眩晕的效果分析

Effect of SRM-IV vertigo diagnosis and treatment system combined with betahistine in the treatment of perivestibular vertigo caused by semicircular canal canalithiasis

目的探讨SRM-IV眩晕诊疗系统联合倍他司汀治疗半规管耳石症致前庭周围性眩晕的效果。方法选取半规管耳石症致前庭周围性眩晕患者204例为治疗对象,根据随机抽签法分为对照组、SRM-IV组、倍他司汀组、联合治疗组,每组51例。对照组采用常规药物治疗,SRM-IV组在对照组基础上增加SRM-IV眩晕诊疗系统治疗,倍他司汀组在对照组基础上增加倍他司汀治疗,联合组在对照组基础上增加SRM-IV组和倍他司汀治疗。综合评估4组患者的症状评分、血流动力学、血清学指标水平、临床疗效、不良反应发生情况。结果治疗后,4组眩晕症状评分简化量表(vertigo symptom score simplified scale,VSS-SF)评分、眩晕障碍量表(vertigo disorder scale,DHI)评分、全血黏度(whole blood viscosity,HBV)、血细胞比容(hematocrit,Hct)、微管相关蛋白(tubule associated protein,Tau)、β淀粉样前体蛋白(βamyloid precursor protein,β-APP)、降钙素基因相关肽(calcitonin gene related peptide,CGRP)水平低于治疗前,Berg平衡量表(Berg balance scale,BBS)评分、椎动脉血流速度、基底动脉血流速度、总有效率高于治疗前,联合组、SRM-IV组、倍他司汀组VSS-SF评分、DHI评分、HBV、Hct、Tau、β-APP、CGRP水平低于对照组,BBS评分、椎动脉血流速度、基底动脉血流速度、总有效率高于对照组,联合组VSS-SF评分、DHI评分、HBV、Hct、Tau、β-APP、CGRP水平低于SRM-IV组、倍他司汀组,BBS评分、椎动脉血流速度、基底动脉血流速度、总有效率高于SRM-IV组、倍他司汀组(P<0.05)。治疗期间4组患者不良反应发生率差异无统计学意义(P>0.05)。结论SRM-IV眩晕诊疗系统联合倍他司汀治疗前庭周围性眩晕效果显著,可改善眩晕症状和血流动力学指标,降低脑损伤标志物水平,治疗安全性良好。

Objective To explore the effect of SRM-IV vertigo diagnosis and treatment system combined with betahistine in the treatment of perivestibular vertigo caused by semicircular canal canalithiasis. Methods A total of 204 patients with perivestibular vertigo caused by semicircular canal canalithiasis were selected as the treatment subjects. They were randomly divided into control group, SRM-IV group, betahistine group and combined treatment group, with 51 cases in each group. The control group was treated with conventional drugs, SRM-IV group was treated with SRM-IV vertigo diagnosis and treatment system on the basis of the control group, betahistine group was treated with betahistine on the basis of the control group, and the combined treatment group was treated with SRM-IV and betahistine on the basis of the control group. The symptom score, hemodynamics, serological index level, clinical efficacy and adverse reactions of the four groups were comprehensively evaluated. Results After treatment, the vertigo symptom score simplified scale(VSS-SF), vertigo disorder scale(DHI) score, high shear whole blood viscosity(HBV), hematocrit(Hct), tubule associated protein(Tau), β-amyloid precursor protein(β-APP), calcitonin gene related peptide(CGRP) level were lower than those before treatment, while Berg balance scale(BBS) score, vertebral artery blood flow velocity, basilar artery blood flow velocity, and total effective rate were higher than those before treatment. VSS-SF score, DHI score, HBV, Hct, Tau, β-APP and CGRP levels were lower than those in the control group, and the BBS score, vertebral artery blood flow velocity, basilar artery blood flow velocity and total effective rate were higher than those in the control group. The VSS-SF score, DHI score, HBV, Hct, Tau, β-APP and CGRP levels were lower than those in SRM-IV group and betahistine group, and the BBS score, vertebral artery blood flow velocity, basilar artery blood flow velocity and total effective rate were higher than those in SRM-IV group and betahistine group(P<0.05). There was no significant difference in the incidence of adverse reactions among the four groups during the treatment(P>0.05). Conclusion SRM-IV vertigo diagnosis and treatment system combined with betahistine is effective in the treatment of perivestibular vertigo, which can improve vertigo symptoms and hemodynamic indexes, reduce the level of brain injury markers, and has good treatment safety.